CD20 (PAN-B CELL) ANTIGEN IS EXPRESSED AT A LOW-LEVEL ON A SUBPOPULATION OF HUMAN LYMPHOCYTES-T

被引:161
|
作者
HULTIN, LE
HAUSNER, MA
HULTIN, PM
GIORGI, JV
机构
[1] UNIV CALIF LOS ANGELES, SCH MED,DEPT MED,CIC,12-939 FACTOR BLDG, 10833 LE CONTE AVE, LOS ANGELES, CA 90024 USA
[2] UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA
来源
CYTOMETRY | 1993年 / 14卷 / 02期
关键词
CD20; LYMPHOCYTE-T; CA-2+ FLUX; FLOW CYTOMETRY; CELL SURFACE ANTIGEN;
D O I
10.1002/cyto.990140212
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Despite the previous description of the leukocyte differentiation antigen CD20 as B cell restricted, the findings reported here indicate that a small subset of human T cells expresses low levels of CD20 or a cross-reacting antigen. Three different CD20 monoclonal antibodies (mAb), Leu16, B1, and 1F5, reacted with the T cell subset. B cells that expressed CD20 were CD20bright and constituted an average of 9.2 +/- 3.3% of adult PBL. Meanwhile, T cells that expressed CD20 were CD20dim and represented 2.4 +/- 1.5% of the PBL. This population may have been overlooked in previous studies due to the low level of CD20 expression per T cell and the small size of the subset in most individuals. Blocking studies indicated that CD20 mAb binding to CD3+ cells was due to the antigen-reactive regions of the CD20 antibodies and was not a result of Fc receptor binding, or non-specific fluorochrome or protein binding. The T cell nature of the CD20dim CD3+ cells was confirmed by the rapid rise in the intracellular calcium concentration ([Ca 2+]i) of CD20dim cells observed following treatment with CD3 mAb but not following treatment with anti-human immunoglobulin (Ig). Extensive three-color immunophenotypic analyses indicated that CD20dim T cells were phenotypically heterogeneous and displayed a leukocyte differentiation profile that was slightly different than that of CD20- T cells. Thus, the CD20dim T cells were more likely than CD20- T cells to be gamma/delta T cell antigen receptor positive (14% vs. 3.4%), CD8+ (57% vs. 33%), and CD45RO+ (82% vs. 51%); fewer were CD38+ (5% vs. 24%) or CD4+ (35% vs. 61%). Given that most differentiation antigens expressed on leukocytes participate in the functions of the cells that express them, it is possible that CD20 plays a role on the T cells on which it is expressed, although the function(s) of the CD20 molecule on T and B cells remains unknown.
引用
收藏
页码:196 / 204
页数:9
相关论文
共 50 条
  • [31] Variable expression and lack of cytokine modulation of the CD20 antigen in human B-cell lymphoma cell lines.
    Pan, DC
    Zelenetz, AD
    Kostmayer, SS
    Giles, F
    Agus, DB
    BLOOD, 1999, 94 (10) : 251B - 251B
  • [32] MULTIPLE B-CELL STIMULATION BY INDIVIDUAL ANTIGEN-SPECIFIC LYMPHOCYTES-T
    PIERCE, SK
    KLINMAN, NR
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1981, 11 (02) : 71 - 75
  • [33] MLR3 MOLECULE IS AN ACTIVATION ANTIGEN SHARED BY HUMAN-B, LYMPHOCYTES-T AND T-CELL PRECURSORS
    RISSO, A
    COSULICH, ME
    RUBARTELLI, A
    MAZZA, MR
    BARGELLESI, A
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1989, 19 (02) : 323 - 328
  • [34] DEVELOPMENTAL REGULATION OF TRANSMEMBRANE SIGNALING VIA THE T-CELL ANTIGEN RECEPTOR/CD3 COMPLEX IN HUMAN LYMPHOCYTES-T
    SANCHO, J
    SILVERMAN, LB
    CASTIGLI, E
    AHERN, D
    LAUDANO, AP
    TERHORST, C
    GEHA, RS
    CHATILA, TA
    JOURNAL OF IMMUNOLOGY, 1992, 148 (05): : 1315 - 1321
  • [35] Combating antigen escape with CD19/CD20 bispecific CAR-T cell therapy
    Zah, Eugenia
    Lin, Meng-Yin
    Jensen, Michael C.
    Silva-Benedict, Anne
    Chen, Yvonne Y.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [36] A Novel Allogeneic γ/δ T Cell Product Targeting CD20 for the Treatment of B Cell Malignancies
    Romero, Jason
    Herrman, Marissa
    Nishimoto, Kevin
    Dahlin, Bernadette
    Chavez, Chris
    Barca, Taylor
    Feathers, Charles
    Lee, Max
    Tayakuniyil, Praveen
    Colantonio, Arnaud
    An, Zili
    Martin, Joel
    Meagher, Craig
    Dilillo, David
    Jing, Frank
    Abbot, Stewart
    Satpayev, Daulet
    MOLECULAR THERAPY, 2019, 27 (04) : 401 - 402
  • [37] A NOVEL LEUKOCYTE DIFFERENTIATION ANTIGEN (VIM-3) EXPRESSED BY MYELOMONOCYTIC CELLS AND ACTIVATED LYMPHOCYTES BUT NOT BY RESTING LYMPHOCYTES-T OR LYMPHOCYTES-B
    WILLIERE, G
    MAJDIC, O
    MAURER, D
    GADD, S
    STOCKINGER, H
    KOLLER, U
    LUTZ, D
    BETTELHEIM, P
    KNAPP, W
    BLUT, 1988, 57 (04): : 188 - 188
  • [38] ACTIVATION OF HUMAN LYMPHOCYTES-T VIA THE CD2 ANTIGEN RESULTS IN TYROSINE PHOSPHORYLATION OF T-CELL ANTIGEN RECEPTOR ZETA-CHAINS
    MONOSTORI, E
    DESAI, D
    BROWN, MH
    CANTRELL, DA
    CRUMPTON, MJ
    JOURNAL OF IMMUNOLOGY, 1990, 144 (03): : 1010 - 1014
  • [39] POLYMORPHISM FOR RHT3, A CD3-LIKE CELL-SURFACE ANTIGEN, EXPRESSED ON RHESUS-MONKEY LYMPHOCYTES-T
    NOOIJ, FJM
    VANVREESWIJK, W
    COOLEN, J
    IMMUNOLOGY, 1986, 59 (04) : 611 - 620
  • [40] Quantitative analysis "at the single cell level" of the novel CD28- CD11b- subpopulation of CD8+ T lymphocytes.
    Lonati, A
    Licenziati, S
    Marcelli, M
    Canaris, D
    Pasolini, G
    Caruso, A
    De Panfilis, G
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (04) : 566 - 566